Please ensure Javascript is enabled for purposes of website accessibility
top of page

‘This is not a science problem anymore': Paths emerge for scaling up rare disease medicine

In 2014, the National Institutes of Health posted an estimate that at the current pace of drug development and approval, it would take 1,000 years to get treatments for the 7,000 known rare diseases.

A paper at the time suggested speeding up that work by grouping together similar diseases, and then treating these patients with the same therapy in a single clinical trial.

Continue Reading Here:

Disclaimer: This document is the work product of the N=1 Collaborative (the “N1C”), and is offered as an example only. The N1C is not providing legal or regulatory advice for N=1 trials. This document should not be construed as legal or regulatory advice for any particular purpose. Any future use of this document should be tailored to specific trials based, for example, on pre-clinical data ASO chemistry and mechanism, patient disease, and evolving body of knowledge, and where appropriate, should separately be subjected to legal review.


Updated November 28, 2023 FDA Clinical Investigator Training Course (CITC) 2023: December 6-7 2023 ABOUT THIS EVENT This course is designed to promote professionalism in the clinical trial industry fo

Updated October 15, 2023 Research technician DCRT: Would you like to develop genetic therapies for patients with rare neurological disorders? Are you interested in using new cellular modelling systems

bottom of page